Management of malignant melanoma: new developments in immune and gene therapy.

Schneeberger, A; Goos, M; Stingl, G; Wagner, S N

Schneeberger, A; Goos, M; Stingl, G; Wagner, S N.

Afiliación

Schneeberger A; Department of Dermatology, Division of Immunology, Allergy and Infectious Diseases, University of Vienna Medical School Austria. Achim.Schneeberger@akh-wien.ac.at

Clin Exp Dermatol ; 25(6): 509-19, 2000 Sep.

Article en En | MEDLINE | ID: mdl-11044187

RESUMEN

Thus far, the use of classical anti-cancer treatment modalities had only rarely a beneficial impact on the prognosis of patients with metastatic melanoma. We as physicians have therefore the obligation as well as the chance to develop and test new therapeutic strategies. Our growing knowledge about the genetic basis of melanoma provides one platform to fulfil this task. Another one comes from our increasing understanding of the molecular and cellular mechanisms involved in the induction/modulation of immune responses, as well as the progress made in the field of identification of melanoma antigens, and allows for the development of a new generation of vaccines. The aim of this article is to discuss several of these new concepts towards the use of immune and gene therapy of melanoma.

Asunto(s)

Vacunas contra el Cáncer/uso terapéutico; Terapia Genética/métodos; Melanoma/terapia; Antígenos de Neoplasias/uso terapéutico; Humanos; Melanoma/inmunología; Melanoma/secundario

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Terapia Genética / Vacunas contra el Cáncer / Melanoma Límite: Humans Idioma: En Revista: Clin Exp Dermatol Año: 2000 Tipo del documento: Article Pais de publicación: Reino Unido

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links